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Altered splicing and cytoplasmic 
levels of tRNA synthetases in 
SF3B1-mutant myelodysplastic 
syndromes as a therapeutic 
vulnerability
Fabio Giuseppe Liberante  1,2, Katrina Lappin1, Eliana M. Barros1, Jekaterina Vohhodina1, 
Florian Grebien2,3, Kienan I. savage1 & Kenneth Ian Mills  1
Myelodysplastic syndromes (MDS) are haematopoietic malignancies that are characterised by a 
heterogeneous clinical course. In recent years, sequencing efforts have uncovered recurrent somatic 
mutations within RNA splicing factors, including SF3B1, SRSF2, U2AF1 and ZRSR2. The most frequently 
mutated gene is SF3B1, mutated in 17% of MDS patients. While SF3B1 mutations and their effects 
on splicing have been well characterised, much remains to be explored about their more far-reaching 
effects on cellular homeostasis. Given that mRNA splicing and nuclear export are coordinated 
processes, we hypothesised that SF3B1 mutation might also affect export of certain mRNAs and 
that this may represent a targetable pathway for the treatment of SF3B1-mutant MDS. We used 
CRISPR/Cas9-genome editing to create isogenic cellular models. Comprehensive transcriptome and 
proteome profiling of these cells identified alterations in the splicing and export of components of the 
translational machinery, primarily tRNA synthetases, in response to the SF3B1 K700E mutation. While 
steady-state protein synthesis was unaffected, SF3B1 mutant cells were more sensitive to the clinically-
relevant purine analogue, 8-azaguanine. In this study, we also demonstrated that 8-azaguanine affects 
splicing. Our results suggest that the simultaneous targeting of RNA metabolism and splicing by 
8-azaguanine represents a therapeutic opportunity for SF3B1-mutant myelodysplastic syndromes.
Myelodysplastic syndromes (MDS) are myeloid haematopoietic malignancies that are characterised by an 
extremely heterogeneous clinical course, ranging from indolent disease without progression, to acute onset 
requiring immediate treatment. The variable course of MDS is mainly driven by molecular heterogeneity. There 
are many genetic defects associated with different prognoses, including numerous deletions and chromosomal 
losses1, implying that the dysplasia of MDS is generally due to loss or alteration of gene function.
In recent years, genome and exome-wide sequencing studies in MDS have uncovered a number of recur-
rent somatic mutations within mRNA splicing factors, including SF3B1, SRSF2, U2AF1 and ZRSR2. The most 
frequent of these were in SF3B1, representing 17% of all mutations in MDS2, which in isolation generally infer 
a better prognosis. This is likely due to their high frequency in the refractory anaemia with ringed sideroblasts 
(RARS) subtype of MDS, which has a clinically more benign phenotype, with a lower likelihood of transforma-
tion. Indeed, mutations of SF3B1 occur in up to 90% of patients with RARS and in 70% of those with refractory 
cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS). The presence of ringed sideroblasts, 
which arise from abnormal iron deposits, was recently demonstrated to be directly related to the presence of 
SF3B1 mutations3. At the molecular level, mutant SF3B1 results in abnormal splicing of several genes, primarily 
due to misrecognition of 3′ splice sites4. Many of the resulting aberrant mRNAs undergo nonsense-mediated 
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mRNA decay (NMD), leading to reduced gene expression. This was shown to affect many genes important for 
iron metabolism in haematopoietic cells, which likely explains the iron transport defects observed in these cells5,6.
While the connection between SF3B1 mutations and its effects on splicing at the molecular level has been 
well characterised7, much remains to be explored about its more far-reaching effects on cell homeostasis. It 
has been known for many years that mRNA splicing and nuclear export are coordinated processes, that are 
tightly-linked8–10. More recent research has begun to demonstrate a direct connection between alternative splic-
ing and cytoplasmic abundance of transcripts as a mechanism of control11,12. Therefore, we hypothesised that 
SF3B1, being a critical part of the spliceosome, might also affect cytoplasmic levels of mRNA species. We sought 
to investigate whether this role of SF3B1 represented a strategy for targeting mutant cells for clinical benefit.
Our data propose that SF3B1 mutations lead to defects in the splicing and export of mRNAs encoding com-
ponents of the translational machinery. While steady-state protein synthesis appears unaffected, SF3B1 mutant 
cells were more sensitive to the clinically-relevant purine analogue, 8-azaguanine. This sensitivity suggests that 
simultaneous targeting of both RNA metabolism and splicing by this single compound represents a therapeutic 
opportunity for patients suffering from SF3B1 mutant myelodysplastic syndromes.
Results
CRISPR/Cas9-edited cells express K700E mutant SF3B1 at equivalent mRNA and protein 
ratios. Whilst a few cell lines harbouring SF3B1 mutations do exist, none is derived from haematopoietic tis-
sues. Therefore, to study the effects of the SF3B1 K700E mutation in isolation, we set out to create isogenic models 
of this mutation in haematopoietic cell lines. K-562 cells were edited using CRISPR/Cas9 and single-stranded 
oligodeoxynucleotides (ssODN) to introduce an A > G substitution in codon 700 of the SF3B1 gene, the mutation 
observed in the majority of MDS patients. A synonymous, tracking mutation was also introduced at codon 701, 
creating a new MspI restriction site (Fig. S1A).
Successful editing of the locus was identified through restriction fragment length polymorphism (RFLP), as 
digestion by MspI would create two fragments instead of one (Fig. S1B). Sanger sequencing of successfully edited 
cells showed a double peak at both the K700E A > G and V701V T > C nucleotides (Fig. 1A). Pyrosequencing of 
DNA and RNA showed that approximately 30% of both DNA and RNA reads contained the mutant A > G allele 
(Fig. 1B). These mutated cells are henceforth designated SF3B1K700E.
Our initial attempts to target a number of other MDS and AML cell lines, including OCI/AML-3 and MDS-L, 
failed. Given that the mutant allele burden in our modified cells deviated significantly from 50%, and an anecdotal 
finding by Zhou et al.13, we hypothesised that it may have been due to these cell lines only harbouring two copies 
of SF3B1. Therefore, we used FISH to assess SF3B1 copy number in these cell lines. This revealed that K-562 cells 
carry at least 3 copies of chromosome 2 and, accordingly, 3 copies of the SF3B1 locus (Fig. 1C). Similarly, testing 
of two other human cancer-derived cell lines that carry SF3B1 K700E mutations (H-2595 and Panc0504) identi-
fied three or more copies of SF3B1. The finding that all reported SF3B1-mutant cell lines (including ESS-1) carry 
three copies of chromosome 2 may reflect a requirement of immortal cell lines for a lower dosage of the mutant 
protein.
Further validation of the mutant clones by T/A cloning of the locus agreed with the FISH and pyrosequencing 
data, showing that mutant cells possessed the A > G transition on only one of three alleles (data not shown). One 
clone, negative by RFLP and designated SF3B1+/Δ/Δ, carried two different out-of-frame deletions; retaining only 
a single functional copy of SF3B1 (Fig. S1C).
In order to verify that the mutated allele was translated into protein, SF3B1 was immunoprecipitated (using an 
N-terminal antibody) from wildtype and SF3B1K700E cells (Fig. S1D) and analysed by mass spectrometry. As the 
K700E mutation destroys a tryptic cleavage site in SF3B1, we were able to confirm the presence of the glutamic 
acid-containing peptide in the successfully mutated clone. In accordance with mRNA expression levels, label-free 
quantitation of peptide fragments estimated that between 32% and 46% of the immunoprecipitated SF3B1 protein 
contained the K700E substitution. This implies that the K700E change does not drastically affect the translation 
or stability of the protein.
SF3B1K700E has similar effects on splicing in primary cells and cell lines. We next set out to deter-
mine if SF3B1 mutation led to altered mRNA-splicing in this model system and whether this altered splicing 
reflected the patterns that are seen in MDS patients and other models of the same mutation. Therefore, publically 
available RNA-Seq data from CD34+ bone marrow cells from MDS patients14 and NALM-6 cell line models4 were 
re-analysed and directly compared.
Initial analysis identified strong inclusion of a cryptic exon within the SNURF/SNRPN gene in SF3B1 mutant 
cells in both public data sets. We determined whether our SF3B1K700E modified cells showed similar inclusion 
of this cryptic exon ‘2b’ by qPCR. We found significantly higher expression levels of the cryptic exon ‘2b’ in the 
SF3B1K700E clone compared to wildtype or +/Δ/Δ cells (Fig. 2A). To enable more comprehensive global compar-
isons, we performed total RNA-Seq on our isogenic cell line model. Encouragingly, increased alternate 3′ splice 
site usage within the ABCB7 gene (chrX:75,071,693-75,071,704 - hg38) was observed in the SF3B1K700E cells 
(Fig. 2B,C), in agreement with what has been identified by a number of groups4,6.
Investigation of differentially spliced transcripts identified significant overlaps between the model gen-
erated in this study and those previously published. In particular, 44.6% of genes that were identified as 
differentially-spliced in our isogenic model were also altered in primary MDS samples with SF3B1K700E mutation 
(Fig. 2D). This suggests a degree of consistency in the effects of SF3B1K700E on the splicing of particular genes, 
despite different cellular contexts. Thus demonstrating the relevance of cell lines as models to study this mutation 
and validating our isogenic model of the SF3B1K700E mutation to physiologically represent changes in RNA splic-
ing and expression as seen in primary patient material.
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Figure 1. (A) Sanger sequencing of the targeted genomic region from both wildtype and K700E mutated 
K-562 cells. Double chromatogram peaks representing different nucleotides are labelled in red. (B) (DNA) 
Pyrosequencing of the targeted genomic region from both wildtype and K700E mutated K-562 cells. The 
calculated allelic ratio is displayed for both the A > G (K700E) and T > C (V701V) nucleotides. The other ratios 
in light grey represent control reactions that ideally yield zero. (RNA) Pyrosequencing of cDNA via RT-PCR 
representing the ratio of RNA species for the same nucleotides. (C) Fluorescent in situ hybridization (FISH) of 
metaphase spreads from normal lymphocytes (NBM), H-2595 (K700E), Panc0504 (K700E) and K-562 cells. 
Blue – DAPI; Green – Whole chromosome 2 paint; Red - Fosmid G248P85642F7 [SF3B1]. All A minimum of 
100 cells scored per cell line. All samples showed ≥3 signals for SF3B1 in ≥85% of cells.
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Interestingly, the majority of differential events in all comparisons were skipped exons, representing more than 
45% of total events in this analysis of the RNA-Seq data (Table 1). This suggests an overall disruption of exon rec-
ognition, despite the more commonly described effect of SF3B1K700E on 3′ splice site recognition15. In contrast to 
the splicing analysis, only 6 down-regulated transcripts overlapped between this study and primary MDS samples 
(Fig. 2E). This illustrates the limitations of whole-transcript level quantitative RNA-Seq in comparing the effects 
of spliceosome mutations on the transcriptome.
On a functional level, enrichment analysis (using Enrichr) of the 548 common differentially-spliced genes 
in all three data sets (Fig. 2D) identified the ribosome, RNA transport and spliceosome pathways (Table 2), as 
significantly altered in SF3B1K700E cells.
SF3B1K700E leads to decreased levels of cytoplasmic mRNA. Numerous studies have demonstrated a 
tight link between RNA splicing and export, demonstrating that efficient splicing is required before RNA export 
can occur16–18. To examine whether SF3B1K700E expression had a global effect on mRNA export (Fig. 3A), we used 
polyA-targeting FISH to localise total mRNA species in both our isogenic K-562 cells and two similar mesothe-
lioma cell lines (Fig. 3B). Quantification revealed that those cells harbouring SF3B1K700E displayed a significant 
increase (~20%) in nuclear mRNA staining intensity (Fig. 3C) compared to their SF3B1WT counterparts, suggest-
ing a defect in mRNA export.
Based on these observations, we set out to examine if SF3B1K700E expression was associated with reduced cyto-
plasmic levels of specific mRNAs. We isolated cytoplasmic and nuclear RNA from WT and SF3B1K700E expressing 
cells. To assess the purity of the samples, we quantified the levels of the nuclear lncRNAs MALAT1 and NEAT119, 
Figure 2. (A) Relative quantities of SNURF exon 2b measured by qPCR across ex2-2b and normalized to ex2-3 
levels. Error bars represent SEM. (B) RNA-Seq, total read count-normalized, coverage plots at the ABCB7 exon 
previously published as having an alternative 3′ splice site. Note: gene is on reverse strand. (C) RT-PCR of cDNA 
from wildtype, SF3B1K700E & SF3B1+/Δ/Δ whole cell (T), nuclear (N) and cytoplasmic fractions (C). Amplicon 
spans ABCB7 exons 8–9 (RefSeq NM_004299). Percentages represent RNA-seq reads that span the alternative 
3′ splice site as a fraction of the total number of reads spanning exons 8 and 9. (D) Venn diagram representing 
overlap in genes identified as having altered splicing by dSpliceType (all types) in SF3B1K700E vs wildtype 
samples. Comparing RNA-Seq data from Darman et al. (NALM-6 cells, n = 3), Dolatshad et al. (primary MDS, 
n = 4) and this study (n = 2). (E) Venn diagram representing overlap in genes identified as downregulated at 
the transcript-level by DESeq. 2 analysis in SF3B1K700E vs wildtype samples. Comparing RNA-Seq data from 
Darman et al. (NALM-6 cells), Dolatshad et al. (primary MDS) and this study.
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which were ≥30-fold enriched in nuclear vs. cytoplasmic fractions (Fig. S2A). Subsequent RNA-seq and data 
analysis confirmed a much greater coverage of MALAT1 and NEAT1 in nuclear RNA fractions compared to 
cytoplasmic fractions (Fig. S2B). The small nucleolar RNA (snoRNA) SNORD47 was also highly enriched in the 
nuclear fraction (Fig. S2B).
RNA-Seq analysis revealed that a higher number of genes were decreased in the cytoplasmic RNA fraction 
of SF3B1 mutant cells than increased (358 vs 168 respectively) (FDR < 0.05 & FC ± 2 | Fig. 4A). An interaction 
network of the under-represented genes (FDR < 0.05 & FC < −1.5 | Fig. 4B) illustrates that not all of the export 
deficient transcripts are actually mis-spliced. This suggests that the SF3B1-related export defect is not always 
related to altered splicing, but may reflect a temporal constraint on co-ordinated splicing and export. The specific 
clusters of genes identified as being down-regulated include components of Aminoacyl-tRNA biosynthesis (blue 
cluster), Biosynthesis of amino acids (mauve cluster) and the TCA cycle (orange cluster). Among the mis-spliced/
lesser-exported genes in the network (49 genes) the pathways Aminoacyl-tRNA biosynthesis (KEGG hsa00970) 
and Cytosolic tRNA aminoacylation (Reactome HSA-379716) were highly enriched (red labels). Sequence anal-
ysis of tRNA synthetase splicing junctions that were altered in SF3B1K700E cells shows that they frequently pos-
sess an AG-GT donor-acceptor consensus site at position −28 (Fig. S2C). Strikingly, we found that 21 of the 44 
human tRNA synthetases (48%) were significantly depleted in the cytoplasmic RNA fraction of SF3B1 mutant 
cells (Fig. S2D | Fig. 4C). Validation by qPCR of tryptophanyl-tRNA synthetase (WARS) showed accumulation of 
nuclear transcripts, but an almost 20% reduction at the cytoplasmic level (Fig. S2E). Taken together, this implies 
a deficiency in tRNA synthesis, caused by the defective splicing and/or export of crucial transcripts in SF3B1 
mutant cells.
SF3B1K700E leads to reduced protein levels of components of the translational machinery 
and tRNA metabolism, but to an increase in spliceosome components. Given the changes in 
mRNA splicing and export observed in the SF3B1K700E cells, we set out to determine the impact of these changes 
on protein expression. To investigate the effects of the SF3B1K700E mutation on the proteome, we used Stable 
Isotopic Labelling by Amino acids in Culture (SILAC). This quantitative mass spectrometry approach identi-
fied a number of proteins whose steady-state levels were altered significantly in SF3B1K700E cells compared 
to wildtype cells. While there was no correlation between transcript and protein levels at the whole cell level 
(Fig. S3A), changes between cytoplasmic transcript and whole cell proteome showed a positive correlation 
(Pearson = +0.294 | Fig. 5A). This is also reflected in the divergence of some transcripts from a general correla-
tion between the three subcellular fractions (Fig. S3B).
Intersection of RNA-seq and SILAC-MS datasets showed that 355 genes had both decreased cytoplasmic 
levels and reduced protein expression upon SF3B1 mutation (Fig. 5B). Indeed, 10 of the 21 tRNA synthetases 
that showed significantly reduced cytoplasmic mRNA levels, were also decreased at the protein level (Table S9). 
Moreover, an interaction network of the proteins down-regulated upon SF3B1 mutation shows enrichment for 
a cluster of genes related to translation (Fig. 5C), the same pathway enriched in all cytoplasm-depleted genes 
(FDR < 0.05). The translation machinery was found among the most strongly down-regulated proteins (>3-fold) 
Type of alteration WT 
vs K700E MDS6 NALM-64
This study 
(whole cell)
A3SS 187 262 405
A5SS 207 180 362
MXE 99 46 249
RI 937 323 580
SE 1385 834 2111
Total unique changes 2815 1421 2896
Up-regulated 156 72 1566
Down-regulated 132 89 1386
Table 1. Differentially spliced or expressed genes for data sets analysed. Numbers represent unique genes. 
Differential expression threshold - fold-change >2 & FDR < 0.05 A3SS/A5SS – alternative 3′/5′ splice site; MXE 
– Mutually exclusive exons; SE – Skipped exons; RI – Retained introns.
Term Overlap Adjusted P-value Z-score Combined Score
Ribosome - hsa03010 15/137 0.0012 −1.75 21.16
RNA transport - hsa03013 15/172 0.0063 −1.84 17.35
Spliceosome - hsa03040 13/134 0.0063 −1.75 16.44
mRNA surveillance pathway - hsa03015 10/91 0.011 −1.64 14.05
Metabolic pathways - hsa01100 53/1239 0.040 −1.91 13.47
Table 2. Enrichr – KEGG 2016 pathway enrichment from 548 genes identified as differentially-spliced in all 
three studies; primary MDS, NALM-6 cell line & this study.
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with some ribosomal proteins (RPS/L) and elongation initiation factors (EIF) decreased at the protein level by 
more than 10-fold (Table S5).
In contrast, the most significantly enriched process among an interaction network of proteins upregulated in 
the SF3B1K700E cells (Fig. 5D) was oxygen transport (GO:0015671). This represents the haemoglobin chains (red 
cluster) — of which 4 subunits were increased >5-fold. In keeping with this, cell pellets from SF3B1 mutant cells 
were consistently redder in colour, reflecting increased haemoglobin levels (Fig. S4A). Components of the RNA 
splicing machinery were also enriched among up-regulated proteins (purple cluster), suggesting a possible feed-
back loop as the cell attempts to compensate for global mis-splicing.
Despite a significant reduction in a number of key ribosomal components at protein, mRNA and tRNA levels, 
SF3B1K700E cells did not show obvious defects in steady-state protein synthesis, as measured via similar rates of 
OP-Puro incorporation into the ribosome (Fig. 5E). Further, the clone possessing only a single functional copy 
of SF3B1 (+/Δ/Δ) also displayed similar rates of protein synthesis, suggesting that SF3B1 copy number alone 
does not influence global protein synthesis rates. Concomitantly, these data imply that SF3B1 mutation leads to 
Figure 3. (A) Schematic illustrating the effects of SF3B1 mutation on splicing and predicted roles in mRNA 
export. (B) FISH of cells fixed and stained with DAPI and Oligo d(T)50-Cy5. H-2595 (SF3B1K700E) & H-2591 
(SF3B1WT) cells were grown directly on slides. K-562 cells were spun onto slides. Images for the same 
fluorophore were captured using identical exposure times and gain. Raw monochrome images colorized using 
ImageJ and overlaid in the final panels. (C) A plot representing the nuclear to cytoplasmic ratio of the Oligo 
d(T)50-Cy5 signal. Multiple FISH images were captured from replicate stainings and cytoplasmic Cy5 signal was 
quantified as a ratio of nuclear signal using an image reduction algorithm written in ImageJ. WT values set as 1. 
Error bars represent SEM.
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Figure 4. (A) Scatter plot of mean cytoplasmic RNA-Seq read counts per gene, as normalised by DESeq2, 
comparing K700E cells to wildtype cells (n = 2). Axes plotted as biexponential (red = FDR < 0.05 FC > 2, 
blue = FDR < 0.05 & FC < −2). (B) Network of directly interacting proteins based on the set of genes identified 
as depleted in the cytoplasmic fraction of mutant cells (FDR0.05 FC < −1.5). Transcripts identified as having 
altered splicing in mutant cells are indicated as diamonds. Genes belonging to tRNA synthesis pathway (KEGG 
hsa00970) are labelled in red. Nodes coloured according to cluster assigned by Reactome FI. Protein-protein 
interactions identified by STRING-DB. Table lists top three enriched pathways for highlighted gene clusters and 
their FDR-adjusted p-values. (C) Plot of –log10(FDR-adjusted p-value) against log2(fold-change) for cytoplasmic 
RNAs WT vs SF3B1K700E –only log2(fold-change) ±1.5 shown (n = 2). Genes from tRNA synthetase pathway 
(KEGG hsa00970) plotted as green triangles. Significantly differentially-expressed tRNA synthetases are 
labelled.
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Figure 5. (A) Scatter plot of log2-transformed protein fold change (SILAC, n = 1, 2702 unique protein hits 
passing QC) vs cytoplasmic transcript log2-transformed fold change (RNA-Seq - DESeq. 2, n = 2). Pearson 
correlation = +0.294. Red = FC > 2 | Blue = FC < −2 in both comparisons. (B) Venn diagram representing 
overlap in genes identified as being depleted in the cytoplasm (FDR < 0.05) and down at the protein level by 
SILAC, comparing SF3B1K700E vs wildtype samples. (C) Network of directly interacting proteins based on those 
identified as being decreased in the SF3B1K700E cells by SILAC. Nodes coloured according to cluster assigned 
by Reactome FI. PPIs identified by STRING-DB (direct, 0.5 confidence). Table identifies top 4 significantly 
enriched gene ontology terms from Reactome, all related to translation (green cluster). (D) Network of directly 
interacting proteins based on those identified as being increased in the K700E cells by SILAC. Nodes coloured 
according to cluster assigned by Reactome FI. PPIs identified by STRING-DB. Table identifies top 4 significantly 
enriched gene ontology terms from Reactome, including oxygen transport (red) and splicing (purple). (E) 
Flow cytometry histograms of cellular fluorescence representing OP-Puromycin (OP-Puro) uptake in wildtype, 
+/Δ/Δ and +/+/K700E cells.
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depletion of tRNA pools through reduced tRNA synthetase levels, combined with a deficiency in translational 
machinery components, without drastically affecting steady-state protein synthesis in non-stressed cells.
SF3B1 mutation increases sensitivity to RNA analogs. Our data show that SF3B1K700E cells have 
defects in the splicing and cytoplasmic export of tRNA synthetases and RNA metabolism-related factors. Given 
this, together with the apparent decrease in ribosomal proteins, we hypothesised that SF3B1K700E cells might be 
hypersensitive to drugs targeting a compromised translational machinery. The nucleoside analogue 8-azaguanine 
is known to incorporate into rRNA and tRNA, and can block regular guanine incorporation20–22. This artificial 
base leads to the production of non-functional RNA species, thereby interfering with ribosome function. Thus we 
hypothesised that 8-azaguanine may selectively target SF3B1K700E cells over ribosome/translation replete wildtype 
cells. Indeed, SF3B1K700E cells were more sensitive to treatment with varying doses of 8-azaguanine (Fig. 6A).
As 8-azaguanine is also incorporated into mRNA species and as guanine is the most frequent base that is 
cleaved before transesterification in the predominant GT/AG cleavage sites, we suspected that its selective effect 
on SF3B1 mutant cells may also be due to an effect on mRNA splicing. To quantify 8-azaguanine-induced changes 
in correct intron removal, we used an exon-intron-exon two-colour fluorescent splicing reporter. Treatment of 
cell lines U2OS and 293-T harbouring this reporter with 8-azaguanine led to a decrease in relative fluorescence 
levels and therefore correct splicing, suggesting that 8-azaguanine does inhibit normal mRNA-splicing functions 
(Fig. 6B).
Discussion
As a health burden, myelodysplastic syndromes represent a considerable proportion of haematological malignan-
cies, constituting 5.7% of total incidence23. Considering that the median age at diagnosis is 75.8 years, the use of 
high-intensity chemotherapy regimens is often not possible due to the lack of fitness of these patients to tolerate 
such therapies, so novel therapeutic options are desperately needed. The discovery of spliceosome mutations in 
myelodysplastic syndromes has led to an explosion of research in this field. Indeed, screening for these mutations 
has identified their presence in many other cancers, including chronic lymphocytic leukaemia (CLL)24, uveal 
melanoma25 and breast cancer26. While a number of novel compound classes have been discovered that target the 
spliceosome machinery directly, such as Spliceostatin A, Pladienolides and more recently H3B-8800, these drugs 
are far from clinical application and some have even proven difficult to synthesise27–29. Therefore, alternative 
means of selectively targeting the SF3B1 mutated cells in patients would be of significant clinical benefit.
There already exist a multitude of recent publications, which investigate the effects of SF3B1 mutations on 
splice-site selection4,7,15,30. Many of these studies have demonstrated that mutant SF3B1 leads to differential 3′ 
splice site preference during splicing. Another recent paper also investigated altered splicing as a signature of 
SF3B1 mutations, showing that it led to a pattern distinct from other spliceosome mutations31. In this study, we 
aimed to identify the downstream effects of SF3B1K700E mutation on cellular homeostasis through modelling of 
isogenic cell lines.
The most immediate effect of introducing the K700E mutation was a change in cell colour, which was reflected 
by an increase in foetal haemoglobin proteins in the SF3B1 mutant clone. This mirrors other research reveal-
ing alterations in haemoglobin synthesis in MDS patients32. Recent screening in healthy elderly populations has 
identified clonal haematopoiesis of indeterminate potential (CHIP) with an increase in the frequency of splice-
osome mutations in haematopoietic stem cells33. While a relatively new concept, some hypothesise that CHIP 
may expand a failing stem cell pool, helping maintain sufficient levels of red blood cells34–36. Therefore SF3B1K700E, 
despite its association with malignant diseases, may initially be beneficial in increasing haemoglobin levels during 
age-related CHIP.
Figure 6. (A) Dose-response curve of 8-azaguanine treatment for 5 days; plotted as % viability as ATP levels 
normalised to vehicle-treated controls. The table represents calculated 50% inhibitory concentrations (IC50) 
and 95% confidence values (n = 3, technical duplicates). (B) Percentage of cells showing wildtype level of 
splicing, as measured by ratio of red to green fluorescence, after treatment with the indicated concentration of 
8-azaguanine. At least 100 cells scored by high-content analysis.
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In comparing our genome-edited cells to existing data sets, we identified the cryptic exon ‘2b’ in the SNURF/
SNRPN gene as strongly preferred in all SF3B1K700E samples considered in this study. This may represent a more 
sensitive surrogate biomarker for SF3B1 mutation in either the clinic or the research laboratory, where clonal 
diversity might mask small minor allele frequencies.
Given the intimate relationship between splicing and nuclear export, we hypothesised that the SF3B1 muta-
tion might lead to a defect in RNA export. While analysis of cytoplasmic RNA-Seq supported this hypothesis, 
it also showed that the effect was not uniform for all transcripts. Reassuringly, the RNA-Seq data from all three 
fractions (total, nuclear, cytoplasmic) correlate reasonably well between wildtype and SF3B1-mutant cells. In con-
trast, the abundances of tRNA synthetase genes were inversely correlated between whole cell extracts and nuclear/
cytoplasmic fractions. This suggests that lower levels of certain cytoplasmic RNAs may not simply be due to 
decreased export, but also decreased transcription in the nucleus or increased exclusion from efficient translation, 
perhaps by sequestration into processing bodies (P-bodies). In line with this, we demonstrated cytoplasmic tran-
script levels correlate with actual protein levels better than total transcript levels, as many mRNAs have recently 
been shown to be only repressed in P-bodies and not decayed37. It has also been shown that other components of 
the nuclear export machinery (NXF1/XPO1) are also mutated in CLL, mutually-exclusive of SF3B1 mutations, 
suggesting that altered export may phenocopy SF3B1 mutation38. However, caution should be used when compar-
ing RNA-Seq quantification between different cellular compartments, as it is known that different fractionation 
methods can yield different estimated transcript levels39. Therefore, we focused our downstream enrichment 
analysis on the cytoplasmic RNA levels.
The most interesting finding was a defect in the splicing and export of mRNAs encoding tRNA synthetases 
and ribosomal components. Additionally, we observed decreased expression of alpha-aminoacyl-tRNA bind-
ing proteins in the SILAC-MS data, concomitant with tRNA depletion. While direct quantification of tRNAs 
is difficult in regular RNA-Seq datasets, this warrants further investigation. Despite these changes, steady-state 
levels of protein synthesis remained unaffected in SF3B1 mutant cells, presumably through up-regulation of com-
pensatory proteins, such as BCLAF1 and SON, which have roles in ribosome biogenesis and mRNA process-
ing40. These proteins may have been upregulated to meet the increased demand of proliferative capacity and thus 
become required to maintain high proliferation rates in SF3B1 mutant cells making them attractive targets for 
splicing-deficient neoplasms.
The relationship between tRNA maintenance and MDS is not entirely new. Sideroblastic anaemia has been 
connected to a mitochondrial tRNA defect in a rare mitochondrial disorder known as mitochondrial myopathy, 
lactic acidosis and sideroblastic anemia (MLASA) syndrome41. Interestingly, one of the functional clusters in 
the network of export-deficient transcripts includes MT-ATP6, whose mutation was associated with MLASA42. 
Furthermore, there is a difference in tRNA levels in MDS compared to healthy haematopoietic tissue43. However, 
these tRNA defects have not yet been associated with altered SF3B1 status.
We theorized that the deficiency in tRNAs and ribosomal components might represent a chemically-tractable 
target in SF3B1 mutant cells. The synthetic nucleoside analogue 8-azaguanine has been investigated for over 70 
years44 and has been reported to have anti-tumour activity in mouse models45. More recent data has shown that it 
is able to induce differentiation in leukaemia cell lines, an effect that was likely mediated through its incorporation 
into tRNA species46. We found that the SF3B1 mutant cells were more sensitive to this compound when compared 
to cells with wild-type SF3B1. While the high doses of 8-azaguanine that were needed for efficacy against leukae-
mia as a single agent led to side effects, it might be used at significantly lower dose in MDS, a much more indolent 
disease, which typically requires lower doses of chemotherapy.
In addition to its well-established effect on tRNA function, our data also show that 8-azaguanine leads to a 
defect in mRNA splicing. Therefore, SF3B1 mutations leading to simultaneous defects in both splicing and tRNA/
ribosome stability might expose a unique vulnerability for dual-targeting using 8-azaguanine. Additionally, 
8-azaguanine does not cross the blood-brain barrier nor is it intercalated or incorporated into DNA. This reduces 
the risk of cerebellar toxicity or therapy-induced leukaemias, which often result from DNA-damaging chem-
otherapies, such as cytarabine and daunorubicin. The dual-targeting effect of 8-azaguanine may also partially 
explain the greater effectiveness of azacytidine in SF3B1 mutant MDS patients as it is also incorporated into RNA/
tRNA47,48.
In conclusion, using isogenic cell systems, we show that the SF3B1K700E mutation induces consistent alterations 
in splicing regardless of cellular context. Additionally, it creates a defect in the nuclear export of polyadenylated 
mRNAs and a dysregulation of tRNA and ribosome homeostasis. Based on its ability to target both tRNA metab-
olism and splicing, we propose a new therapeutic application for the riboside analogue 8-azaguanine in treating 
patients harbouring SF3B1 mutations, such as breast cancer, uveal melanoma, myelodysplastic syndromes, acute 
myeloid leukaemia and beyond.
Materials and Methods
Published data analysis. RNA-Seq data from SF3B1 mutant NALM-6 cells was published by Darman et al.4 
(NCBI PRJNA295064; GEO: GSE72790)4. RNA-Seq data from MDS patients and healthy donors was published 
by Dolatshad et al. (NCBI PRJNA268220; GEO: GSE63569)14. Both datasets were downloaded as raw FASTQ 
reads and processed using the same pipeline.
Cell lines. K-562 cells, obtained from DSMZ, were maintained in RPMI-1640 (Sigma Aldrich), supplemented 
with FBS Superior (Biochrom AG) and 1% Penicillin/Streptomycin (Gibco) at 37 °C 5% CO2. In the case of 
long-term culture for dilution cloning, complete media was supplemented with 2 mM HEPES (Sigma-Aldrich) 
and 1 mM UltraGlutamine I (Lonza Biochem).
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Plasmids. The pSpCas9(BB)-2A-GFP (PX458) plasmid was a gift from Feng Zhang49 (Addgene plasmid # 
48138). The pmKaxxte plasmid (now available as Addgene plasmid #113630), used to check gRNA efficiency, 
was generated using the pmaxGFP vector (Lonza) as a backbone and the mKate2.5-C1 — a gift from Michael 
Davidson (Addgene plasmid # 54828) — to generate overlapping insert fragments and a multiple cloning site.
The RFP2GFP-ATM construct was generated by inserting RFP sequence from mKate2.5-C1 into the pmax-
GFP vector between KpnI and AgeI sites. The sequence encoding the ATM exon20-intron20-exon21 was PCR 
amplified from 293 T derived genomic DNA using primer sequences in Table S1 and cloned into the vector’s ORF 
between RFP and GFP tags using HindIII and SalI enzymes.
CRISPR/Cas9. Guide RNAs (gRNA) were chosen using the online tool designed by Zhang et al. ssODNs were 
designed that contained the desired substitutions together with 77 bp of homology either side of the targeted sub-
stitutions. The gRNAs were tested using the mKaxxte plasmid (Addgene #113630) containing a cloned fragment 
of the intended target genomic region. This assessed the effectiveness of DSB creation by the gRNA by triggering 
HR-repair of the template to re-establish fluorescence. The final gRNA chosen yielded bright fluorescence in 
the majority of control cells, compared to those without the gRNA, which showed no background fluorescence 
(Fig. S4C).
The ssODN and gRNA/SpCas9-expressing plasmid (gRNA cloned into Addgene #48138) were nucleofected 
into K-562 cells. Cells were then sorted to purity for GFP-positivity and sub-cloned by dilution. The mutant allele 
burden and mRNA expression level was checked by Pyrosequencing.
FISH & T/A cloning. FISH analysis was performed at the Wellcome Centre for Human Genetics, Oxford. For 
polyA FISH, cells were stained with fluorescent Oligo(d)T50 probes, as previously described16.
The targeted genomic region was amplified by PCR and then T/A cloned. At least 9 clones from each sample 
were sequenced.
Proteomics. For SILAC, cells were grown in either “light” or “medium” RPMI and crude lysates analysed by 
FingerPrints Proteomics, Dundee. Data were analysed using MaxQuant software. For protein synthesis measure-
ments, the EZClick™ Global Protein Synthesis Assay Kit (BioVision Inc., USA) kit was utilised.
Splicing reporter assay. In the assay, a reporter plasmid encodes green and red fluorescent proteins sepa-
rated by a human ATM intron fragment containing stop codons in all frames (RFP2GFP-ATM); successful splic-
ing leads to an equivalent ratio of green and red fluorescence. U2OS and 293 T cells were seeded in 6 well glass 
bottom plates. The following day, cells were treated with 0.1, 0.5, 1 or 5 μM 8-Azaguanine. Approximately 5 hours 
later, cells were transfected with the RFP2GFP-ATM construct and incubated for further 48 hours. Following this, 
single cell RFP and GFP fluorescence intensity was acquired in 10,000 cells/well using high-content imaging and 
splicing was assessed as the GFP/RFP fluorescence intensity ratio relative to control/untreated cells.
RNA-Seq. Nuclear and Cytoplasmic RNAs were separated using a hypotonic buffer. RNA-Seq libraries were 
prepared using the SMARTer® Stranded Total RNA Sample Prep Kit (634873 Clontech). Sequencing reads were 
aligned using STAR50, transcripts quantified using DESeq251 and differential splicing analysed by dSpliceType52. 
Random subsampling analysis via RSeQC53 showed that the read coverage approached saturation of identified 
splice junctions, meaning that, statistically, all known and many of the novel junctions would have likely been 
identified at the coverage level achieved for all samples (Fig. S4D).
Data Availability
The RNA-Seq dataset generated during the current study is available in the ArrayExpress (EMBL-EBI) repository, 
under accession E-MTAB-7192. The proteomics dataset generated during the current study will be made available 
in the ProteomeXchange repository. All other data generated and analysed during this study are included in this 
published article (and its Supplementary Information files).
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